ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
AssigneesAbbVie Inc., AbbVie Biotherapeutics Inc.
InventorsKurt C. GISH, Jonathan A. HICKSON, Susan Elizabeth MORGAN-LAPPE, James W. PURCELL
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
Claims32
A method of treating a huLRRC15 stromal(+)/cancer(+) tumor, comprising administering to a human having a huLRRC15 stromal(+)/cancer(+) tumor an amount of an anti-huLRRC15 ADC sufficient to provide therapeutic benefit, wherein the ADC comprises a DNA intercalating agent linked to an anti-huLRRC15 antibody by way of a linker according to a structure of formula (I):
- [D-L-XY-]n-Ab (I)
- or a salt thereof, wherein:
- D is the DNA intercalating agent;
- L is the linker;
- Ab is the anti-huLRRC15 antibody;
- XY represents a covalent linkage linking linker L to antibody Ab;
- and
- n is an integer ranging from 2 to 8;
- wherein
- Ab comprises
- a VH chain corresponding in sequence to SEQ ID NO:16 and a VL chain corresponding in sequence to SEQ ID NO:17,
- a VH chain corresponding in sequence to SEQ ID NO:26 and a VL chain corresponding in sequence to SEQ ID NO:27,
- a VH chain corresponding in sequence to SEQ ID NO:36 and a VL chain corresponding in sequence to SEQ ID NO:37,
- a VH chain corresponding in sequence to SEQ ID NO:46 and a VL chain corresponding in sequence to SEQ ID NO:47,
- a VH chain corresponding in sequence to SEQ ID NO:56 and a VL chain corresponding in sequence to SEQ ID NO:57,
- a VH chain corresponding in sequence to SEQ ID NO:66 and a VL chain corresponding in sequence to SEQ ID NO:67, or
- a VH chain corresponding in sequence to SEQ ID NO:76 and a VL chain corresponding in sequence to SEQ ID NO:77.
A method of treating a huLRRC15 stromal(+)/cancer(+) tumor, comprising administering to a human having a huLRRC15 stromal(+)/cancer(+) tumor an amount of an anti-huLRRC15 ADC sufficient to provide therapeutic benefit, wherein the ADC comprises an antimitotic agent linked to an anti-huLRRC15 antibody by way of a linker according to a structure of formula (I):
- [D-L-XY-]n-Ab (I)
- or a salt thereof, wherein:
- D is the antimitotic agent;
- L is the linker;
- Ab is the anti-huLRRC15 antibody;
- XY represents a covalent linkage linking linker L to antibody Ab;
- and
- n is an integer ranging from 2 to 8;
- wherein
- Ab comprises
- a VH chain corresponding in sequence to SEQ ID NO:16 and a VL chain corresponding in sequence to SEQ ID NO:17,
- a VH chain corresponding in sequence to SEQ ID NO:26 and a VL chain corresponding in sequence to SEQ ID NO:27,
- a VH chain corresponding in sequence to SEQ ID NO:36 and a VL chain corresponding in sequence to SEQ ID NO:37,
- a VH chain corresponding in sequence to SEQ ID NO:46 and a VL chain corresponding in sequence to SEQ ID NO:47,
- a VH chain corresponding in sequence to SEQ ID NO:56 and a VL chain corresponding in sequence to SEQ ID NO:57,
- a VH chain corresponding in sequence to SEQ ID NO:66 and a VL chain corresponding in sequence to SEQ ID NO:67, or
- a VH chain corresponding in sequence to SEQ ID NO:76 and a VL chain corresponding in sequence to SEQ ID NO:77.
Dependencies are inferred from the claim text.